CA 19-9 as a biomarker in advanced pancreatic cancer patients randomised to gemcitabine plus axitinib or gemcitabine alone

BACKGROUND: Response assessment in advanced pancreatic cancer (APC) is difficult and predictive markers are needed. There are insufficient data on the value of carbohydrate antigen 19–9 (CA 19-9) and cytostatic-targeted therapies. Axitinib, a selective vascular endothelial growth factor (VEGF) recep...

Descripción completa

Detalles Bibliográficos
Autores principales: Wasan, H S, Springett, G M, Chodkiewicz, C, Wong, R, Maurel, J, Barone, C, Rosbrook, B, Ricart, A D, Kim, S, Spano, J-P
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2009
Materias:
Molecular Diagnostics
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768104/
https://www.ncbi.nlm.nih.gov/pubmed/19724276
http://dx.doi.org/10.1038/sj.bjc.6605243

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2768104/
https://www.ncbi.nlm.nih.gov/pubmed/19724276
http://dx.doi.org/10.1038/sj.bjc.6605243

Ejemplares similares